

**AREA PRESCRIBING COMMITTEE – ACTION LIST 15<sup>th</sup> OCTOBER 2015**

Action Reference	Minute Reference	ACTION	OWNER	FURTHER COMMENTS	TARGET DATE	STATUS (R/A/Clear)
14/050	134/14	Draft a formal statement about the second line use of anti-TNFs for psoriatic arthritis in line with the decisions of the IFR panel.	LA	To be added to Blueteq	17.12.2015	RED ONGOING
<b>ACTIONS FOR 2015</b>						
15/16	33/15	<b>NICE CG Medicines Optimisation</b> The CCG part completed Baseline Assessment was discussed. This is to become a standing agenda item with discussion focusing on: <ul style="list-style-type: none"> <li>Medicines and patient safety</li> <li>Patient decision aids</li> </ul>	PU  BG PB	Provider Trusts to bring completed Baseline Assessments to the next meeting	17.12.2015	ONGOING
15/20	54/15	<b>NTAG-Rituximab for Immune Thrombocytopenic Purpura</b>	LA	LA to seek information on position in other NE CCG's	17.12.2015	ONGOING
15/34	72/15	<b>NG 14-Melanoma – assessment &amp; management</b>	LA	Review current Vitamin D guidelines to ensure NG14 is followed	17.12.2015	ONGOING
15/36	106/15	<b>Green Bag Scheme</b> BG to check with NWAS if there are any schemes running currently in the North West.	BG	Possible future topic for the North West Clinical Pharmacy Forum	17.12.15	ONGOING
15/37	108/15	<b>Guidelines for the use of Feminising Hormone therapy in gender dysphoria</b> Suggested changes to include local details to be incorporated into document and brought back to next meeting for approval	LA		17.12.2015	ONGOING

15/38	109/15	<b>Guidelines for the use of Masculinising Hormone therapy in gender dysphoria</b> Suggested changes to include local details to be incorporated into document and brought back to next meeting for approval	LA		17.12.2015	ONGOING
15/39	111/15	<b>Sulfasalazine SCG</b> PB to check with gastroenterologists whether gastro indications should be included; query re requirements for patient monitoring	PB		17.12.2015	ONGOING
15/40	120/15	<b>Leflunomide SCG</b> Final version to be brought to the next meeting for final approval	PB		17.12.2015	ONGOING
15/41	123/15	<b>DRUG SAFETY UPDATE</b>  Risk of Subcutaneous Lupus Erythrematosus with PPI's – add to Prescription Pad  The Cumbria yellow card report to be brought to next meeting	LA   AL		17.12.2015  17.12.2015	